The PANDORA project: results of the cost of illness analysis

被引:7
作者
Esposti, ED [1 ]
Berto, P [1 ]
Ruffo, P [1 ]
Buda, S [1 ]
Esposti, LD [1 ]
Sturani, A [1 ]
机构
[1] Ravenna Local Hlth Unit, Hlth Directorate, I-48100 Ravenna, Italy
关键词
cost of illness; antihypertensive drugs; general practitioner;
D O I
10.1038/sj.jhh.1001178
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aims: To evaluate the cost of illness from hypertension for the Italian National Health System (NHS), Methods and Results: A prospective analysis was carried out on clinical and economic data recorded in the general practitioners' (GPs) database, Twenty-one GPs working in the Ravenna area in Italy took part in the project on a voluntary basis. The study included 1047 hypertensive patients enrolled between 1 June and 31 December 1997 and continued for 365 days from the date of enrolment, The following costs were calculated: antihypertensive drugs, laboratory tests and instrumental procedures, GP visits for blood pressure control, specialist visits, casualty visits, hospitalisation due to cardiovascular problems. In the whole sample, the most relevant cost is due to antihypertensive drugs (42.7%), followed by hospital admission (28.4%), GP visits (15.1%) and tests (10.6%), The total mean cost was significantly lower in incident (no previous treatment) than in prevalent patients (already treated) (457 512 vs 725 573 Italian Lira (ITL), P < 0.05) and in older rather than in younger patients (1171 410 vs 796 452 (ITL) P < 0.05), (In the text the equivalent is given in Euros, Pounds Sterling and US dollars). Conclusion: Our study should be considered as preliminary, nevertheless it could represent a step towards the evaluation of the true cost of hypertension.
引用
收藏
页码:329 / 334
页数:6
相关论文
共 14 条
  • [1] Health and disease management: What is it and where is it going? What is the role of health and disease management in hypertension?
    Bernard, DB
    Townsend, RR
    Sylvestri, MF
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (08) : 103S - 108S
  • [2] CAMPBELL GR, 1996, PHARMACARE EC, V11, P16
  • [3] COLLINS R, 1994, TXB HYPERTENSION, P1150
  • [4] Drummond M, 1992, Pharmacoeconomics, V2, P1, DOI 10.2165/00019053-199202010-00001
  • [5] The Pandora Project: Results of the pilot study
    Esposti, ED
    Berto, P
    Buda, S
    Di Nardo, AM
    Sturani, A
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (08) : 790 - 796
  • [6] ESPOSTI ED, 1999, MECOSAN, V31, P93
  • [7] HEALTH-CARE COSTS FOR EMPLOYED HYPERTENSIVES
    HEBEL, JR
    MCCARTER, RJ
    SEXTON, M
    [J]. MEDICAL CARE, 1990, 28 (05) : 446 - 457
  • [8] HODGKINSON DP, 1983, RADIOACT WASTE MANAG, V4, P129
  • [9] Johannesson M, 1991, Scand J Prim Health Care, V9, P155, DOI 10.3109/02813439109018511
  • [10] Blood-pressure control in the hypertensive population
    Mancia, G
    Sega, R
    Milesi, C
    Cesana, G
    Zanchetti, A
    [J]. LANCET, 1997, 349 (9050) : 454 - 457